The United Kingdom and the United States have announced a important trade agreement that will ensure no tariffs on British drug products being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost spending on medicines through the public health system. This move ensures that tariffs on these key products will stay at nothing for a duration of three years.
This deal follows recent warnings to hike duties on patented pharmaceutical products, with potential rates floated reaching double the cost.
"This arrangement between the UK strengthens the international landscape for new treatments and introduces much-needed fairness to U.S.–U.K. drug exports," an announcement said.
Economic Impact
Medicines represent one of the UK's biggest exports to the America, which is by far the primary destination for leading British pharmaceutical firms.
Export figures reveal that in the year to the end of the third quarter, the UK exported pharmaceutical products totaling billions to the US. This value represented 17.4% of total UK exports in that span.
"This agreement safeguards work, boosts funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a government official commented.
Key NHS Changes
The pact includes several specific changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise total health service expenditure on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. Last year, repayments exceeded 20%.
Recent Tensions
This agreement takes place against a long-running dispute between the drug companies and the ministers over medicine costs and approval rates.
These tensions were exacerbated by assertions that US consumers were charged several times more for the identical medicines than consumers in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
